Ivabradine treatment lowers blood pressure and promotes cardiac and renal protection in spontaneously hypertensive rats.
Nenhuma Miniatura disponível
Data
2022
Autores
Título da Revista
ISSN da Revista
Título de Volume
Editor
Resumo
Hypertension is linked to hyperpolarization-activated cyclic nucleotide-gated (HCN) function, expressed in
excitable and non-excitable cells. Considering that the reduction in heart rate (HR) improves coronary perfusion
and cardiac performance, ivabradine (IVA) emerged as an important drug for the treatment of cardiovascular
diseases.
Aim: Evaluate if IVA chronic treatment effect can mitigate hypertension and reverse the cardiac and renal
damage in SHR.
Main methods: Rats were divided into 4 groups treated for 14 days with PBS (1 ml/kg; i.p) or IVA (1 mg/kg; i.p):
1) WKY PBS; 2) SHR PBS; 3) WKY IVA; and 4) SHR IVA. The systolic blood pressure (SBP) was measured,
indirectly, before and during the treatment period with IVA (day 0, 1, 7 and 11). Rats were subjected to artery
cannulation for direct blood pressure (BP) measurement. Morphofunctional and gene expression were evaluated
in the heart and kidneys.
Key findings: IVA reduced SBP only in SHR on the 7th day. Direct blood pressure measurement showed that IVA
chronic treatment reduced HR in the SHR. Interestingly, mean arterial pressure (MAP) was reduced in SHR IVA
when compared to SHR PBS. Serum and urinary biochemical data were not altered by IVA. Moreover, IVA
reduced the renal inflammatory infiltrates and increased glomerular density, besides preventing the cardiac
inflammatory and hypertrophic responses.
Significance: IVA treatment lowered blood pressure, improved cardiac remodeling and inflammation, as well as
decreasing renal damage in SHR. Further, IVA increased renal HCN2 mRNA and reduced cardiac HCN4 mRNA.
Descrição
Palavras-chave
Ivabradine, HCN channels, Blood pressure, Hypertension, Renal and cardiac inflammatory response
Citação
GOMES, F. A. R. et al. Ivabradine treatment lowers blood pressure and promotes cardiac and renal protection in spontaneously hypertensive rats. Life Sciences, v. 308, artigo 120919, 2022. Disponível em: <https://www.sciencedirect.com/science/article/pii/S0024320522006191>. Acesso em: 01 ago. 2023.